[Pharmacogenetics of depression in elderly patients]

Area of Science:

• Pharmacology
• Genetics
• Geriatrics

Context:

• Depression is a leading cause of disability, often treated with antidepressant pharmacotherapy.
• Antidepressant treatment is limited by delayed efficacy and side effects.
• Elderly patients face increased risks of adverse drug events due to physiological changes and polypharmacy.

Purpose:

• To explore the role of pharmacogenetics in optimizing antidepressant treatment for depression.
• To identify genetic factors influencing treatment response (efficacy, onset, adverse events) in depressed elderly individuals.
• To bridge the gap between pharmacogenetic research and clinical practice.

Summary:

• Pharmacogenetics evaluates the human genome's impact on drug response, offering a path to "tailored" medication.
• Studies have investigated candidate genes like CYP2D6 and serotonin transporter genes in depressed subjects.
• Existing research shows promise, but more studies are needed, particularly in elderly populations.

Impact:

• Personalized pharmacotherapy can enhance antidepressant efficacy and minimize adverse drug events.
• Pharmacogenetics holds the potential to improve treatment outcomes for depressed elderly patients.
• Further research is crucial for integrating pharmacogenetic insights into routine clinical practice for depression management.